46 results
P
adults (≥18 years of age)
I/C
PM10 exposure, MI
O
increased risk of MI
P
MI-MVD, E-MVD
I/C
Microscopic microvascular decompression, Endoscopic microvascular decompression, MI-MVD vs E-MVD
O
Patient effective rate, Detection rate of offensive blood vessels, Total complication rate, Recurrence rate
P
patients with left main coronary artery disease
I/C
percutaneous coronary intervention (PCI) with drug-eluting stents, coronary artery bypass graft (CABG)
O
all-cause mortality, myocardial infarction (MI), stroke, repeated revascularization, periprocedural MI, nonperiprocedural MI
P
patients with MI, coronary bifurcation lesions, short or long lesions, and unprotected left main coronary artery stenosis (ULMCA)
I/C
IVUS-guided PCI, angiography-guided PCI
O
MACEs (including ST, MI, cardiac death, and all-cause death), target lesion revascularization (TLR), target vessel revascularization (TVR)
P
individuals
I/C
precise attention, preventive planning, accelerated rate
O
complications of MI
P
1,626,910 participants
I/C
Exposure to road traffic noise (RTN), Different noise exposure groups
O
Myocardial infarction (MI)
P
People with multiple sclerosis (PwMS)
I/C
Non-MS population
O
Prevalence of myocardial infarction (MI)
P
stable coronary artery disease (CAD) patients
I/C
coronary bypass (CABG), stenting, optimal medical therapy (OMT), OMT, CABG, durable-polymer-CoCr-everolimus-eluting stent, bio-absorbable-polymer-CoCr-sirolimus eluting stent
O
all-cause mortality, myocardial infarction (MI)
P
patients without previous myocardial infarction
I/C
increased total bilirubin (TB) levels, patients with normal TB levels
O
reduced risk of long-term (>3 year) first MI
P
patients with established cardiovascular disease (CVD) or high cardiovascular risks
I/C
anti-inflammatory therapies, placebo
O
decreased incidence of myocardial infarction (MI), reduced risks of heart failure, lower incidence of stroke